We have an extensive network of industry and academic contacts, including executives at Delphi-funded companies, scientists and clinicians. Because many of our partners have been senior managers at, or advisors to, healthcare companies, our network includes top-level business and medical professionals around the world. We're also involved in unique industry and academic initiatives like the Stanford University Bio-X program. As an early stage investor, Delphi gets an early look at market developments and advances that will shape the evolution of the rapidly growing $100 billion-plus world-wide medical device industry for the coming decade. Additionally, we draw on our extensive network of biotech clinical and scientific thought leaders and executives for deal flow and diligence that allows us to stay on the forefront of breakthroughs in biology, chemistry, and technology that will drive innovation in drug discovery and development.